{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:52:04Z","timestamp":1791114724942,"version":"4.1.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"DOI":"10.1038\/s41433-026-04916-0","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:04:58Z","timestamp":1790964298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Three-year real-world outcomes of faricimab in pretreated eyes with treatment-resistant neovascular age-related macular degeneration"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4574-1291","authenticated-orcid":false,"given":"Pierluigi","family":"Daniele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4787-0666","authenticated-orcid":false,"given":"Christine","family":"Goodchild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-5832","authenticated-orcid":false,"given":"Eslam","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7220-7809","authenticated-orcid":false,"given":"Anastasios","family":"Bisoukis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4990-9413","authenticated-orcid":false,"given":"Serena","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"4916_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914\u201326.","journal-title":"Ophthalmology"},{"key":"4916_CR2","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (Lond). 2024;38:3059\u201364.","journal-title":"Eye (Lond)"},{"key":"4916_CR3","doi-asserted-by":"publisher","first-page":"596406","DOI":"10.2147\/OPTH.S596406","volume":"20","author":"E Ahmed","year":"2026","unstructured":"Ahmed E, Goodchild C, Bisoukis A, Salvatore S. Two-year real-world outcomes of faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2026;20:596406.","journal-title":"Clin Ophthalmol"},{"key":"4916_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-15194-3","volume":"15","author":"M Saito","year":"2025","unstructured":"Saito M, Imaizumi K. Two-year results of switching to intravitreal administration of faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration. Sci Rep. 2025;15:30699.","journal-title":"Sci Rep"},{"key":"4916_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3928\/23258160-20260127-02","volume":"57","author":"N Mohan","year":"2026","unstructured":"Mohan N, Schulgit MJ, Bellanda V, Barbosa GCS, Szigiato A, Talcott KE, et al. Long-term outcomes of faricimab in previously treated neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2026;57:220\u20136.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04916-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04916-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04916-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:01:50Z","timestamp":1791111710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04916-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":5,"alternative-id":["4916"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04916-0","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"15 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS is an advisory board member for Advanz Pharma, Bayer, Alimera Sciences and Roche; has received speaker honoraria from AbbVie, Alimera Sciences, Bayer, Roche and Sandoz; and has received travel support from Alimera Sciences, Bayer and Roche. PD, EA and AB declare no competing interests. CG received travel support from Alimera Sciences, AbbVie, Santen and Roche, and speaker honoraria from Roche and Scope.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}